INDIA-FIRST AUTONOMOUS DRUG DISCOVERY

From molecule.
To experiment.
To medicine.

AI designs. Autonomous systems execute. Evidence determines what happens next. BayesPharma Labs is building the experimental execution layer around BayesPharma AI so scientific decisions can become governed experiments, evidence and better next decisions.

Enter Digital Lab →Explore Pipeline
● SOFTWARE AUTONOMY · LIVEDIGITAL TWIN · LIVEPHYSICAL LAB · STAGED

BUILT TODAY

Prove the software before buying the hardware.

The operating layer is visible now. Physical automation is deliberately staged behind qualification, measured-data and safety gates.

BAYESPHARMA AILIVE

Scientific intelligence, discovery workflows and next-decision context.

software
AUTONOMY OSCHECKING

Protocol compilation, scheduling, recovery, QC and provenance.

software
DIGITAL TWINCHECKING

Virtual workcells and governed rehearsal of execution paths.

simulated
VIRTUAL DEVICES—

Redundant adapters for barcode, liquid handling, incubation and readout.

operational
DIGITAL MATURITY—

BayesPharma internal autonomy maturity, derived only after persisted runs.

internal metric
PHYSICAL DEVICES0

No commissioned BayesPharma physical robotics are claimed today.

staged
Global status language: ● LIVE SOFTWARE · ◆ SIMULATED · ◐ STAGED · ○ PLANNEDInspect the Digital Lab →
02SYSTEM

ONE SYSTEM · TWO LAYERS

The intelligence layer meets the execution layer.

BayesPharma AI decides what science is worth doing next. BayesPharma Labs is being built to execute that science reproducibly. Evidence then returns to the programme rather than disappearing into disconnected tools.

SCIENTIFIC INTELLIGENCElive software

BayesPharma AI

Drug-discovery and development decision intelligence connecting scientific evidence, models, uncertainty and the next experiment.

Target biologyMolecular designDocking + physicsADMETSynthesis intelligenceEvidence reasoningCandidate rankingNext experiment
Explore BayesPharma AI ↗
SIGNEDPROTOCOL
IR
EXPERIMENTAL AUTONOMYlive software

BayesPharma Labs

The governed experimental control plane: qualify intent, schedule devices, execute bounded work, recover, run QC and preserve evidence provenance.

Protocol compilerDigital TwinDevice schedulingVirtual roboticsFault recoveryAutomated QCEvidence provenanceMission Control
Run the Digital Lab →
QUESTION→AI / MODELS→EXPERIMENT CONTRACT→LAB EXECUTION→EVIDENCE→LEARN→NEXT DECISION

THE SCIENTIFIC GATE

Choose the right problem before optimizing the machinery.

Science should be easier to inspect than the technology around it. Every programme has to earn its next experiment through progressively sharper questions.

01 · DISEASEIs the unmet need important?

Define a clinically meaningful problem and the population where improvement matters.

02 · TARGETIs the biology causal and tractable?

Interrogate genetics, mechanism, safety, modality and structural opportunity.

03 · MOLECULECan intervention become chemistry?

Turn biology into a testable chemical hypothesis with developability constraints visible.

04 · EXPERIMENTWhat result could kill the hypothesis?

Design the evidence-generating step before treating a prediction as progress.

03PIPELINE

INDIA-FIRST RESEARCH PORTFOLIO

Start where unmet need meets scientific leverage.

These are research priorities, not clinical assets. The portfolio is currently at target-selection / scientific-diligence stages and is designed to progress only when evidence earns the next gate.

01
METABOLIC

Type 2 diabetes + obesity

Incretin signalling · insulin sensitization · differentiated oral hypotheses
TARGET SELECTION
NEXT GATEBiology · tractability · safety
→ 02
CARDIOMETABOLIC

Hypertension + heart failure + dyslipidemia

Resistant hypertension · HFpEF biology · residual lipid risk
TARGET SELECTION
NEXT GATECausality · phenotype · safety window
→ 03
ONCOLOGY · INDIA-FIRST

Oral & head-and-neck cancer

Precision small molecules · resistance biology · combination-ready design
TARGET SELECTION
NEXT GATEBiomarker · tractability · therapeutic window
→ 04
ONCOLOGY

Breast cancer / triple-negative disease

TNBC vulnerabilities · biomarker-linked design · synthetic lethality
TARGET SELECTION
NEXT GATEVulnerability · selectivity · resistance logic
→ 05
AMR · INDIA-FIRST

Carbapenem-resistant Gram-negative infections

Lol transport · Gram-negative penetration · resistance-aware design
TARGET SELECTION
NEXT GATEEssentiality · tractability · resistance frequency
→

Stage labels describe the current scientific gate; they do not imply nominated candidates, validated biology or clinical-stage status.

View all priority programmes →
04LOOP

DESIGN → MAKE → TEST → LEARN

A result matters only if it changes what happens next.

One candidate should move from hypothesis to execution to evidence without losing provenance, uncertainty or the scientific reason for the next decision.

05LAB

DIGITAL AUTONOMOUS LABORATORY

Software autonomy now. Physical automation next.

The homepage now observes the same Autonomy OS used by the public Digital Lab and Mission Control. The visual facility is a digital workcell representation; physical execution remains qualification-gated.

AUTONOMY OS · CONNECTINGVIRTUAL DEVICES · —RUNS · —RECOVERIES · —
SYNC · —
DIGITAL ROBOTIC FACILITYCONNECTING TO DIGITAL LAB
simulated workcells
01 · IDENTITY
Barcode + sample gateIdentity before execution
02 · DISPENSE
Robotic liquid handlingAssay preparation
03 · INCUBATE
Controlled incubationBounded timing + temperature
04 · READ
Multimode readoutResult → QC → evidence
06EVIDENCE

CANDIDATE EVIDENCE PASSPORT

Never let a model output masquerade as experimental truth.

One compact record makes the scientific boundary legible: how a result was produced, its evidence class, QC state, provenance and whether physical execution actually occurred.

LATEST DIGITAL RECORDNo run yet
governed origin

BP-DIGITAL-LAB

Evidence classes stay distinct through every handoff. A simulation can be useful operational evidence without becoming a measured assay.

BINDING / METHODSDeterministic calculationCOMPUTED
ADMET / MODELSModel estimate + applicabilityPREDICTED
DIGITAL LABSIMULATED_NOT_MEASUREDSIMULATED
PHYSICAL ASSAYRequires qualified executionNOT CLAIMED
HUMAN DECISIONAccountable interpretationREVIEWED
PROVENANCE SUMMARYLatest persisted autonomy record
inspectable
PROTOCOLAwaiting run
EVIDENCE ORIGINSimulation boundary
QC DECISION—
Z′—
PHYSICAL EXECUTIONNO
EVIDENCE BOUNDARYENFORCED
Operating principle: provenance should survive every handoff from computation to decision.COMPUTED ≠ PREDICTED ≠ SIMULATED ≠ MEASURED ≠ REVIEWED
07BUILDOUT

FROM SOFTWARE TO PHYSICAL AUTONOMY

Build the laboratory in earned stages.

Capital and complexity should accumulate only when the previous layer has taught us enough to justify the next. Selecting a phase explains the roadmap; it does not claim that phase exists today.

PHASE 0 · CURRENT FOUNDATION

WHY THIS PHASE
SCOPE
GATE TO EARN
NON-NEGOTIABLEQualification before autonomy. Evidence origin never silently upgrades.
Digital
Twin
Measured
Bridge
Robotic
Biology
Analytical
QC
Automated
Chemistry
Bounded
Autonomy

BUILT FROM INDIA

India became the pharmacy of the world.
Now build more discovery here.

India already has deep strength in chemistry, pharmaceutical manufacturing, clinical expertise and scientific talent. The next opportunity is to connect those strengths with modern scientific AI, automation and evidence-governed experimental infrastructure so more original medicines can begin here.

THE ENDPOINT

The goal isn't more experiments.
It's better medicines.

Learn sooner. Stop weak hypotheses earlier. Advance stronger candidates with evidence, uncertainty and accountability still attached.

Enter Digital Lab →Explore PipelineInvestor Briefing